SCHEMBL893700

SCHEMBL893700

C1=C(c2ccccc2)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28559478 0.94 ALDH1A1 (0.53)
SCHEMBL3224933 0.79 SIGMAR1 (0.39)
SCHEMBL272499 0.78 SIGMAR1 (0.52)
SCHEMBL7959398 0.77 CFTR (0.48)
SCHEMBL10198086 0.77 MAT2A (0.45)
SCHEMBL9988136 0.75 SIGMAR1 (0.50)
SCHEMBL9988138 0.75 SIGMAR1 (0.50)
SCHEMBL28554683 0.73 ALDH1A1 (0.50)
SCHEMBL41762 0.69
SCHEMBL7212942 0.69 ALDH1A1 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389464-B2 Arginase inhibitors as therapeutics MARS, INCORPORATED (US) 2022-07-19 US disclosed
EP-3719024-A1 ARGINASE INHIBITORS AS THERAPEUTICS Mars, Incorporated (US) 2020-10-07 EP disclosed
US-20200246362-A1 Arginase Inhibitors as Therapeutics MARS, INCORPORATED 2020-08-06 US disclosed
CN-106008569-B9 Borate as arginase inhibitor and composition and application thereof 马尔斯公司 2020-05-22 CN disclosed
EP-3034509-B1 ARGINASE INHIBITORS AS THERAPEUTICS MARS INC (US) 2020-04-22 EP disclosed
CN-106008569-B Borate as arginase inhibitor and composition and application thereof 马尔斯公司 2020-04-03 CN disclosed
US-10603330-B2 Arginase inhibitors as therapeutics MARS, INCORPORATED (US) 2020-03-31 US disclosed
US-20190054101-A1 ARGINASE INHIBITORS AS THERAPEUTICS MARS, INCORPORATED 2019-02-21 US disclosed
EP-2560978-B1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS INC (US) 2019-01-30 EP disclosed
US-20180296532-A1 RNA-Focused Small Molecules for Inhibiting RNA Toxicity in Myotonic Dystrophy SCRIPPS RESEARCH INST (US) 2018-10-18 US disclosed
EP-2561754-A2 CYCLOPROPENE COMPOUND, AND METHOD FOR ADDING SAME TO CROPS Erum Biotechnologies Inc. (KR) 2013-02-27 EP disclosed
US-20120322662-A1 CYCLOPROPENES AND METHOD FOR APPLYING CYCLOPROPENES TO AGRICULTURAL PRODUCTS OR CROPS ERUM BIOTECHNOLOGIES INC. (KR) 2012-12-20 US disclosed
US-20120149708-A1 MODULATORS OF VIRAL TRANSCRIPTION, AND METHODS AND COMPOSITIONS THEREWITH GEORGE MASON UNIVERSITY 2012-06-14 US disclosed
US-20120129806-A1 ARGINASE INHIBITORS AS THERAPEUTICS MARS, INCORPORATED 2012-05-24 US disclosed
US-20120083469-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2012-04-05 US disclosed
WO-2011133653-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED (US) 2011-10-27 WO disclosed
WO-2010005384-A1 KETONE PYRIDINE ANALOGUES AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS ASTRAZENECA AB (SE) 2010-01-14 WO disclosed
US-6767856-B1 OLEFIN POLYMERIZATION CATALYST COMPRISING CATIONIC COMPLEX THAT RESULTS FROM CONTACT OF NEUTRAL TRANSITION METAL COMPOUND TO ACTIVATOR COMPOSITION UNIVATION TECHNOLOGIES, LLC 2004-07-27 US disclosed
EP-1311557-A1 TRANSITION METAL OLEFIN POLYMERIZATION CATALYST HAVING CYCLOPROPENYL DERIVED LIGANDS Univation Technologies LLC (US) 2003-05-21 EP disclosed
WO-2002012351-A1 TRANSITION METAL OLEFIN POLYMERIZATION CATALYST HAVING CYCLOPROPENYL DERIVED LIGANDS UNIVATION TECHNOLOGIES, LLC (US) 2002-02-14 WO disclosed